Skip to main content
. 2020 Feb 10;11(8):2329–2338. doi: 10.7150/jca.37708

Table 1.

Patient Information and Dosimetric Parameters

Histology/ Stage Patients (n) Median Percentage/ Range
Male 102 86·5%
Female 16 13·5%
Age 60 years 36-79 years
Histology squamous 41 34·7%
adeno 19 16·1%
small cell 53 44·9%
other 5 4·2%
Stage I-II 7 5·9%
III 86 72·9%
IV 25 21·2%
Smoker 97 82·2%
Non-smoker 21 17·8%
COPD 40 33·9%
With former surgery 10 8·5%
With chemotherapy or targeted therapy 114 96·6%
Primary tumor dose 61·6 Gy 30-70 Gy
MLD 11·6 Gy 3.3-19 Gy
V30 12·0% 2·0%-23·1%
V20 20·0% 2·0%-30·5%
V10 34·2% 4·0%-60·0%
V5 51·0% 13·8%-86·0%
Follow-up time 314 days 37-614 days
RP grade≥2 patient 50 42·4%
median interval to RP grade≥2 diagnosis 86 days 33-205 days

COPD= chronic obstructive pulmonary disease; MLD= mean lung dose in Gy; V30, V20, V10, V5= the percentage of the lung volume (with subtraction of the volume involved by lung cancer) which receives radiation doses of 30, 20, 10, 5 Gy or more.